{"id":"placebo-for-naloxone","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3249799","moleculeType":"Small molecule","molecularWeight":"327.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos contain no active drug and produce no direct biochemical effect. In the context of a naloxone trial, the placebo arm allows researchers to isolate the true pharmacological benefit of naloxone (opioid antagonism) from placebo response, natural disease progression, and other non-specific factors. This is a standard methodological tool in randomized controlled trials rather than a therapeutic agent.","oneSentence":"A placebo is an inert substance with no active pharmacological mechanism, used as a control in clinical trials to measure the effect of naloxone independent of psychological expectation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:58.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials evaluating naloxone efficacy"}]},"trialDetails":[{"nctId":"NCT07459166","phase":"PHASE2","title":"A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade","status":"NOT_YET_RECRUITING","sponsor":"Clear Scientific, Inc.","startDate":"2026-04","conditions":"Fentanyl Overdose, Fentanyl Poisoning","enrollment":16},{"nctId":"NCT05458609","phase":"PHASE3","title":"Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2023-02-09","conditions":"Alcohol Use Disorder","enrollment":8},{"nctId":"NCT05430152","phase":"PHASE2","title":"Low-dose Naltrexone for Post-COVID Fatigue Syndrome","status":"COMPLETED","sponsor":"Luis Nacul","startDate":"2024-01-15","conditions":"Post-Viral Fatigue Syndrome","enrollment":160},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT07249554","phase":"PHASE2","title":"Combination Therapy for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-05","conditions":"Alcohol Use Disorder","enrollment":45},{"nctId":"NCT04851301","phase":"PHASE1, PHASE2","title":"Neural Mechanisms of Immersive Virtual Reality in Chronic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":259},{"nctId":"NCT07433413","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Sciencare Medical Industries Co., Ltd.","startDate":"2026-03-15","conditions":"Alcohol Use Disorder (AUD)","enrollment":240},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT05063201","phase":"PHASE2","title":"Cariprazine for Comorbid Cocaine and Opioid Use Disorder","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2022-08-05","conditions":"Opioid-use Disorder, Cocaine Use Disorder","enrollment":26},{"nctId":"NCT03482479","phase":"PHASE2","title":"Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-02-04","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis","enrollment":60},{"nctId":"NCT06306157","phase":"PHASE4","title":"Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2024-01-02","conditions":"Complex Regional Pain Syndrome, Chronic Pain, Causalgia","enrollment":40},{"nctId":"NCT07221565","phase":"PHASE1, PHASE2","title":"Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting","status":"ENROLLING_BY_INVITATION","sponsor":"Truway Health, Inc.","startDate":"2025-10-23","conditions":"Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis","enrollment":120},{"nctId":"NCT04791969","phase":"PHASE2","title":"Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM","status":"COMPLETED","sponsor":"Glenn-Milo Santos","startDate":"2021-12-14","conditions":"Methamphetamine Use Disorder","enrollment":60},{"nctId":"NCT04600089","phase":"PHASE2","title":"Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","status":"RECRUITING","sponsor":"Sam Tyagi","startDate":"2020-12-08","conditions":"Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm","enrollment":30},{"nctId":"NCT04166071","phase":"EARLY_PHASE1","title":"Opioids and Social Support Enhanced Extinction Effects","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Los Angeles","startDate":"2021-12-13","conditions":"Fear","enrollment":60},{"nctId":"NCT03608163","phase":"PHASE4","title":"Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2019-01-08","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":4},{"nctId":"NCT05073679","phase":"PHASE2, PHASE3","title":"Oral Naltrexone In Pediatric Eating Disorders","status":"TERMINATED","sponsor":"Rosemary Claire Roden","startDate":"2022-04-22","conditions":"Anorexia Nervosa/Bulimia, Anorexia in Adolescence, Anorexia Nervosa, Atypical","enrollment":9},{"nctId":"NCT06809166","phase":"PHASE4","title":"Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","status":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-07-04","conditions":"Obesity, Weight Loss, Weight Management","enrollment":40},{"nctId":"NCT05976646","phase":"PHASE1, PHASE2","title":"Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2023-09-18","conditions":"Addiction, Opioid Use, Substance Use Disorders","enrollment":18},{"nctId":"NCT04744883","phase":"EARLY_PHASE1","title":"Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2020-08-15","conditions":"Chronic Low-back Pain","enrollment":140},{"nctId":"NCT03897998","phase":"PHASE2","title":"Neural Correlates of Hypoalgesia Driven by Observation","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":182},{"nctId":"NCT00006203","phase":"PHASE4","title":"Naltrexone, Craving, and Drinking","status":"COMPLETED","sponsor":"Brown University","startDate":"","conditions":"Alcoholism","enrollment":180},{"nctId":"NCT05011266","phase":"PHASE2, PHASE3","title":"Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-04-18","conditions":"Opioid-use Disorder","enrollment":180},{"nctId":"NCT06494904","phase":"PHASE3","title":"Standard Versus High Dose ED-Initiated Buprenorphine Induction","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-06","conditions":"Opioid Use Disorder","enrollment":360},{"nctId":"NCT03751111","phase":"PHASE1, PHASE2","title":"Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2019-02-13","conditions":"Chronic Pruritus","enrollment":126},{"nctId":"NCT02330419","phase":"PHASE2","title":"Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-04","conditions":"Binge Drinking, HIV","enrollment":120},{"nctId":"NCT04678895","phase":"PHASE2","title":"Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2020-12-22","conditions":"Painful Diabetic Neuropathy","enrollment":35},{"nctId":"NCT05007561","phase":"EARLY_PHASE1","title":"Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences","status":"RECRUITING","sponsor":"San Diego State University","startDate":"2021-11-16","conditions":"Naltrexone, Placebo","enrollment":210},{"nctId":"NCT02461927","phase":"PHASE1, PHASE2","title":"Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-01-01","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":65},{"nctId":"NCT06406400","phase":"PHASE1","title":"Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-05-13","conditions":"Opioid Use Disorder","enrollment":15},{"nctId":"NCT04473950","phase":"PHASE1","title":"The Effect of Chronic Pain on Delay Discounting in Methadone Patients","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2020-01-08","conditions":"Opioid-use Disorder, Chronic Pain Syndrome","enrollment":10},{"nctId":"NCT06251609","phase":"PHASE2","title":"Naloxone for Opioid Associated Out of Hospital Cardiac Arrest","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-11","conditions":"Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone","enrollment":98},{"nctId":"NCT04313972","phase":"PHASE4","title":"IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone","status":"TERMINATED","sponsor":"Endeavor Health","startDate":"2021-09-07","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome","enrollment":3},{"nctId":"NCT04818086","phase":"PHASE1, PHASE2","title":"Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2021-05-03","conditions":"Drug Interaction, Analgesics, Opioid Use Disorder","enrollment":18},{"nctId":"NCT05062577","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-11-08","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT01950520","phase":"PHASE2","title":"Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-07","conditions":"Healthy Volunteers","enrollment":47},{"nctId":"NCT06622239","phase":"PHASE2","title":"Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-12-01","conditions":"Nonsuicidal Self-Injury","enrollment":150},{"nctId":"NCT05609877","phase":"NA","title":"The NONA-LISA Trial","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-06-01","conditions":"Respiratory Distress Syndrome in Premature Infant","enrollment":324},{"nctId":"NCT04547985","phase":"PHASE4","title":"Naltrexone Treatment for Prolonged Grief Disorder (PGD)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-01-05","conditions":"Prolonged Grief Disorder","enrollment":9},{"nctId":"NCT04976855","phase":"PHASE1","title":"Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2022-08-17","conditions":"Healthy Volunteer, Opioid-use Disorder","enrollment":64},{"nctId":"NCT06426303","phase":"PHASE4","title":"Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder","status":"RECRUITING","sponsor":"Milky Kohno","startDate":"2024-05-02","conditions":"Alcohol Use Disorder","enrollment":100},{"nctId":"NCT05363514","phase":"PHASE4","title":"Low Dose Naltrexone Use in Patients With POTS","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2025-01","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":80},{"nctId":"NCT04739995","phase":"PHASE4","title":"Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-06-01","conditions":"Randomized Controlled Trial","enrollment":99},{"nctId":"NCT05093296","phase":"PHASE2, PHASE3","title":"Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2021-12-02","conditions":"Alcohol Use Disorder, Alcoholism, Alcohol Addiction","enrollment":62},{"nctId":"NCT02806440","phase":"PHASE4","title":"Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism?","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2016-06","conditions":"Fibromyalgia","enrollment":58},{"nctId":"NCT06245902","phase":"PHASE2","title":"An Acute Migraine Factorial Study","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-02-18","conditions":"Migraine With or Without Aura","enrollment":92},{"nctId":"NCT04450316","phase":"PHASE2","title":"Low-dose Naltrexone for Bladder Pain Syndrome","status":"SUSPENDED","sponsor":"Stanford University","startDate":"2020-10-08","conditions":"Bladder Pain Syndrome, Interstitial Cystitis","enrollment":40},{"nctId":"NCT04854551","phase":"PHASE1, PHASE2","title":"Opioid Modulation and Neural Reward Activation in Healthy Adults","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-05-01","conditions":"Alcohol Drinking, Opioid Use, Unspecified","enrollment":13},{"nctId":"NCT04249882","phase":"PHASE2","title":"A Novel Human Lab Model for Screening AUD Medications","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2020-01-28","conditions":"Alcohol Use Disorder","enrollment":53},{"nctId":"NCT05301712","phase":"PHASE4","title":"A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke","status":"COMPLETED","sponsor":"Samjin Pharmaceutical Co., Ltd.","startDate":"2018-08-07","conditions":"Stroke, Acute","enrollment":446},{"nctId":"NCT05955313","phase":"PHASE2","title":"Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia","status":"RECRUITING","sponsor":"Medical University of Lublin","startDate":"2023-05-31","conditions":"Vulvodynia, Naltrexone, Quality of Life","enrollment":300},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT05037032","phase":"PHASE4","title":"Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude","status":"COMPLETED","sponsor":"VA Loma Linda Health Care System","startDate":"2021-08-08","conditions":"Altitude, Sleep Apnea, Central","enrollment":16},{"nctId":"NCT02700048","phase":"PHASE1, PHASE2","title":"Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2016-06","conditions":"Hypoglycemia Unawareness, Type 1 Diabetes","enrollment":11},{"nctId":"NCT00271024","phase":"PHASE2","title":"Efficacy of Naltrexone in Women's Smoking Cessation","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2005-12","conditions":"Smoking, Smoking Cessation","enrollment":333},{"nctId":"NCT00775229","phase":"PHASE2","title":"Naltrexone in the Treatment of Trichotillomania","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2008-08","conditions":"Trichotillomania","enrollment":51},{"nctId":"NCT00053677","phase":"PHASE3","title":"Drug Treatment for Pathologic Gambling Disorder","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2002-12","conditions":"Gambling","enrollment":83},{"nctId":"NCT04270877","phase":"PHASE2","title":"Fibromyalgia and Naltrexone: The FINAL Study","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2021-01-06","conditions":"Fibromyalgia","enrollment":99},{"nctId":"NCT04052139","phase":"PHASE2","title":"St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2021-01-25","conditions":"Chronic Pain, Alcohol Use, Unspecified, HIV Infections","enrollment":45},{"nctId":"NCT02811783","phase":"PHASE3","title":"Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL","status":"TERMINATED","sponsor":"Elorac, Inc.","startDate":"2017-01","conditions":"Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome","enrollment":59},{"nctId":"NCT02543944","phase":"PHASE2, PHASE3","title":"Improving Treatment Outcomes for Prescription Opioid Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2016-02","conditions":"Drug Dependence","enrollment":117},{"nctId":"NCT04365985","phase":"PHASE2","title":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-04-29","conditions":"COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS)","enrollment":70},{"nctId":"NCT02137252","phase":"PHASE2","title":"Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-05","conditions":"Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ","enrollment":3},{"nctId":"NCT01402492","phase":"PHASE2, PHASE3","title":"Cocaine Use Reduction With Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-09","conditions":"Cocaine Dependence","enrollment":302},{"nctId":"NCT01866098","phase":"NA","title":"Naltrexone for Antipsychotic-Induced Weight Gain","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-05","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":144},{"nctId":"NCT01527994","phase":"PHASE1","title":"Aprepitant Effects in Intravenous Heroin Dependence","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-01","conditions":"Opioid Dependence","enrollment":64},{"nctId":"NCT04154033","phase":"PHASE2","title":"Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2020-10-01","conditions":"Atopic Dermatitis, Pruritus, Dermatitis","enrollment":""},{"nctId":"NCT03061734","phase":"PHASE2","title":"Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-02-18","conditions":"Migraine With or Without Aura","enrollment":92},{"nctId":"NCT03185143","phase":"PHASE2, PHASE3","title":"Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-06-27","conditions":"Migraine With and Without Aura","enrollment":36},{"nctId":"NCT01415895","phase":"PHASE2","title":"Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain","status":"COMPLETED","sponsor":"Annette C. Toledano MD","startDate":"2011-07","conditions":"Back Pain, Lower Back Pain, Cervical Pain","enrollment":78},{"nctId":"NCT03008590","phase":"PHASE2","title":"Low Dose Naltrexone for Chronic Pain From Arthritis","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-05-01","conditions":"Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic","enrollment":29},{"nctId":"NCT04738773","phase":"PHASE2","title":"RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2021-06-01","conditions":"Eye Tracking, Gambling Disorder, Naltrexone","enrollment":40},{"nctId":"NCT02322047","phase":"PHASE2","title":"Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2015-03-03","conditions":"Alcohol Use Disorder, Posttraumatic Stress Disorder (PTSD)","enrollment":31},{"nctId":"NCT04649892","phase":"PHASE2","title":"Predicting Response to Naltrexone With Eye Tracking in Videogame Disorder","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2021-01","conditions":"Gaming Disorder","enrollment":40},{"nctId":"NCT00129246","phase":"PHASE1, PHASE2","title":"Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain","status":"COMPLETED","sponsor":"Yale University","startDate":"2004-12","conditions":"Smoking, Nicotine Dependence","enrollment":40},{"nctId":"NCT01882361","phase":"PHASE2, PHASE3","title":"Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-06","conditions":"Opiate Dependence, Human Immunodeficiency Virus","enrollment":77},{"nctId":"NCT03518021","phase":"PHASE3","title":"Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2018-05-15","conditions":"Overdose, Drug Abuse","enrollment":286},{"nctId":"NCT02469077","phase":"NA","title":"Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-08","conditions":"Chronic Pain","enrollment":117},{"nctId":"NCT02581111","phase":"PHASE2, PHASE3","title":"Naloxone for Optimizing Hypoxemia Of Lung Donors","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-09","conditions":"Brain Death, Organ Donors, Lung Transplantation","enrollment":199},{"nctId":"NCT00142818","phase":"PHASE2","title":"Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2006-02","conditions":"Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders","enrollment":164},{"nctId":"NCT01550341","phase":"NA","title":"HIV, Buprenorphine, and the Criminal Justice System","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-02-23","conditions":"Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction","enrollment":50},{"nctId":"NCT00568958","phase":"PHASE4","title":"Naltrexone for Heavy Drinking in Young Adults","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-02","conditions":"Alcohol Consumption, Alcoholic Intoxication, Alcoholism","enrollment":140},{"nctId":"NCT01246401","phase":"PHASE1, PHASE2","title":"Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-03","conditions":"HIV, AIDS, Opioid Dependence","enrollment":151},{"nctId":"NCT01053078","phase":"PHASE1, PHASE2","title":"Naltrexone and Hypoglycemia in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2009-10","conditions":"Type 1 Diabetes, Hypoglycemia Unawareness","enrollment":29},{"nctId":"NCT04115020","phase":"PHASE2","title":"Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-01","conditions":"Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic","enrollment":""},{"nctId":"NCT00817089","phase":"PHASE4","title":"Understanding Treatment Response With Naltrexone Among White Alcoholics","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-12","conditions":"Alcoholism","enrollment":24},{"nctId":"NCT00115037","phase":"PHASE4","title":"Managing Alcoholism in People Who Do Not Respond to Naltrexone","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2003-09","conditions":"Alcoholism","enrollment":302},{"nctId":"NCT03854942","phase":"PHASE1","title":"Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2011-08-30","conditions":"Alcohol Addiction","enrollment":43},{"nctId":"NCT02651584","phase":"PHASE3","title":"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-12","conditions":"Opioid Use Disorders","enrollment":428},{"nctId":"NCT00256451","phase":"PHASE4","title":"Endophenotype for Alcohol Misuse in Healthy Minority Populations","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2005-11","conditions":"Healthy","enrollment":43},{"nctId":"NCT03132571","phase":"PHASE2","title":"Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-06-01","conditions":"Schizophrenia, Diabetes Mellitus, Type 2, Obesity","enrollment":5},{"nctId":"NCT02026011","phase":"PHASE2","title":"Naltrexone for Individuals of East Asian Descent","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-12","conditions":"Alcohol Use Disorder","enrollment":87},{"nctId":"NCT03430180","phase":"PHASE2","title":"Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder","status":"UNKNOWN","sponsor":"Finnish Institute for Health and Welfare","startDate":"2018-02-22","conditions":"Pathological Gambling, Gambling Disorder, Opioid Antagonist","enrollment":126},{"nctId":"NCT02181231","phase":"PHASE1, PHASE2","title":"Buprenorphine Used With Treatment Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-06-01","conditions":"Major Depressive Disorder, Depression","enrollment":18},{"nctId":"NCT02696434","phase":"PHASE3","title":"Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-04","conditions":"Opioid Use Disorder","enrollment":101},{"nctId":"NCT01549652","phase":"NA","title":"5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-04","conditions":"Opioid Withdrawal, Physical Dependence","enrollment":133},{"nctId":"NCT00020605","phase":"PHASE3","title":"Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain","status":"UNKNOWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2000-05","conditions":"Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT01999114","phase":"PHASE1","title":"The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2012-03","conditions":"ECG Effects","enrollment":328},{"nctId":"NCT00663117","phase":"PHASE2","title":"The Effects of Naltrexone on Active Crohn's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2006-09","conditions":"Inflammation, Crohn's Disease","enrollment":40},{"nctId":"NCT00715117","phase":"PHASE2","title":"The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-07","conditions":"Crohn's Disease","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo (for Naloxone)","genericName":"Placebo (for Naloxone)","companyName":"Albert Einstein College of Medicine","companyId":"albert-einstein-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo is an inert substance with no active pharmacological mechanism, used as a control in clinical trials to measure the effect of naloxone independent of psychological expectation. Used for Control arm in clinical trials evaluating naloxone efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}